Los Angeles Capital Management LLC Reduces Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Los Angeles Capital Management LLC decreased its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 59.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 872,605 shares of the biotechnology company's stock after selling 1,284,391 shares during the period. Los Angeles Capital Management LLC owned approximately 0.32% of Exelixis worth $32,217,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of EXEL. Coppell Advisory Solutions LLC bought a new position in Exelixis in the fourth quarter valued at about $25,000. Colonial Trust Co SC grew its stake in Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 765 shares during the period. Bartlett & CO. Wealth Management LLC acquired a new stake in Exelixis in the first quarter valued at approximately $37,000. Crowley Wealth Management Inc. acquired a new stake in Exelixis in the fourth quarter valued at approximately $50,000. Finally, Hurley Capital LLC purchased a new position in shares of Exelixis during the fourth quarter valued at approximately $68,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Down 0.5%

EXEL stock traded down $0.21 during midday trading on Monday, hitting $44.26. The company's stock had a trading volume of 1,796,448 shares, compared to its average volume of 2,535,035. Exelixis, Inc. has a 52-week low of $22.20 and a 52-week high of $49.62. The firm has a market capitalization of $12.07 billion, a P/E ratio of 20.59, a PEG ratio of 0.89 and a beta of 0.28. The firm has a 50-day simple moving average of $43.17 and a 200-day simple moving average of $38.47.

Insider Transactions at Exelixis

In other Exelixis news, Director Jack L. Wyszomierski sold 7,535 shares of Exelixis stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $43.09, for a total value of $324,683.15. Following the transaction, the director directly owned 358,882 shares in the company, valued at approximately $15,464,225.38. The trade was a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Amy C. Peterson sold 72,776 shares of the business's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the transaction, the chief marketing officer owned 465,393 shares in the company, valued at approximately $21,161,419.71. This trade represents a 13.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 458,113 shares of company stock valued at $21,024,817 over the last quarter. 2.85% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on EXEL shares. Wells Fargo & Company reissued a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Royal Bank Of Canada restated a "sector perform" rating and issued a $50.00 target price (up from $45.00) on shares of Exelixis in a research note on Tuesday, July 8th. UBS Group set a $43.00 target price on Exelixis and gave the company a "neutral" rating in a research note on Friday, July 11th. JMP Securities boosted their target price on Exelixis from $47.00 to $50.00 and gave the company a "market outperform" rating in a research note on Monday, June 23rd. Finally, HC Wainwright boosted their target price on Exelixis from $47.00 to $53.00 and gave the company a "buy" rating in a research note on Monday, June 30th. One analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, Exelixis currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.28.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.